Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | PPARD | Q03181 | 6/20 | 0.41 |
| ▸ | PPARA | Q07869 | 6/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011462 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL2010277 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL2011728 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL14894607 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| SCHEMBL398562 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| Methane SCHEMBL2010948 | 0.98 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| Methane SCHEMBL2010999 | 0.98 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| Methane SCHEMBL2009500 | 0.98 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| Methane SCHEMBL2012154 | 0.98 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNANFKB1PMP22 | |
| Methane SCHEMBL14152353 | 0.98 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNANFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10154981-B2 | Use of a feed composition for reducing methane emission in ruminants, and/or to improve ruminant performance | DSM IP ASSETS B.V. (NL) | 2018-12-18 | — | — | US | claimed |
| EP-3041365-B1 | USE OF A FEED COMPOSITION FOR REDUCING METHANE EMISSION IN RU-MINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS BV (NL) | 2018-04-04 | — | — | EP | claimed |
| US-20160183564-A1 | USE OF A FEED COMPOSITION FOR REDUCING METHANE EMISSION IN RUMINANTS, AND OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS B.V. (NL) | 2016-06-30 | — | — | US | claimed |
| US-9365489-B2 | Nitrooxy alkanoic acids and derivatives thereof in feed for reducing methane emission in ruminants, and/or to improve ruminant performance | DSM IP ASSETS B.V. (NL) | 2016-06-14 | — | — | US | claimed |
| CN-103561586-B | Fodder compound is for reducing the discharge of methane of ruminant and/or improving the purposes that ruminant shows | DSM IP ASSETS B.V. (NL) | 2016-05-04 | — | — | CN | claimed |
| CN-105472995-A | Use of feed composition for reducing methane emission in ru-minants, and/or to improve ruminant performance | DSM IP ASSETS BV | 2016-04-06 | — | — | CN | claimed |
| US-20140134282-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS B.V. (NL) | 2014-05-15 | — | — | US | claimed |
| EP-2509435-B1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS BV (NL) | 2014-02-26 | — | — | EP | claimed |
| US-20120315339-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | DSM IP ASSETS B.V. (NL) | 2012-12-13 | — | — | US | claimed |
| WO-2025151713-A1 | PROTEIN AND PEPTIDE VACCINES TARGETING METHANOGENS | Arkea Bio Corp. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025151711-A1 | NUCLEIC ACID VACCINES TARGETING METHANOGENS | Arkea Bio Corp. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20250222082-A1 | PROTEIN AND PEPTIDE VACCINES TARGETING METHANOGENS | ARKEA BIO CORP (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025128700-A1 | CELL-BASED VACCINES | Arkea Bio Corp. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250186566-A1 | CELL-BASED VACCINES | ARKEA BIO CORP (US) | 2025-06-12 | — | — | US | disclosed |
| CN-100496490-C | Nitrooxy derivatives of losartan, valsartan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin II receptor blockers for the treatment of cardiovascular diseases | NICOX SA (FR) | 2009-06-10 | — | — | CN | disclosed |
| EP-1653950-B1 | NITROOXY DERIVATIVES OF LOSARTAN, VALSATAN, CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX SA (FR) | 2008-01-09 | — | — | EP | disclosed |
| US-20060276523-A1 | Nitoroxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-II receptor blockers for the treatment of cardiovascular diseases | NICOX S.A. (FR) | 2006-12-07 | — | — | US | disclosed |
| CN-1832742-A | Nitrooxy derivatives of losartan, valsartan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin II receptor blockers for the treatment of cardiovascular diseases | NICOX SA (FR) | 2006-09-13 | — | — | CN | disclosed |
| EP-1653950-A2 | NITROOXY DERIVATIVES OF LOSARTAN, VALSATAN, CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Nicox S.A. (FR) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011646-A2 | NITROOXY DERIVATIVES OF LOSARTAN, VALSATAN, CANDESARTAN, TELMISARTAN, EPROSARTAN AND OLMESARTAN AS ANGIOTENSIN-II RECEPTOR BLOCKERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | NICOX S.A. (FR) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134282-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | PIGS, TECR, CYP4X1 | ALDH1A1 2126/4885TSHR 630/4885LMNA 901/4885 |
| US-20250186566-A1 | CELL-BASED VACCINES | HAGH, HSD17B10, FH | ALDH1A1 1304/4885TSHR 4160/4885LMNA 4854/4885 |
| US-20120315339-A1 | NITROOXY ALKANOIC ACIDS AND DERIVATIVES THEREOF IN FEED FOR REDUCING METHANE EMISSION IN RUMINANTS, AND/OR TO IMPROVE RUMINANT PERFORMANCE | PIGS, TECR, CYP4X1 | ALDH1A1 2126/4885TSHR 630/4885LMNA 901/4885 |
| US-20250222082-A1 | PROTEIN AND PEPTIDE VACCINES TARGETING METHANOGENS | MCRS1, VIP, HM13 | ALDH1A1 4837/4885TSHR 3446/4885LMNA 4701/4885 |
| US-10154981-B2 | Use of a feed composition for reducing methane emission in ruminants, and/or to improve ruminant performance | OAT, MRM1, ETFA | ALDH1A1 2035/4885TSHR 2374/4885LMNA 4078/4885 |
| US-20060276523-A1 | Nitoroxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-II receptor blockers for the treatment of cardiovascular diseases | AGTR2, AGTR1, REN | ALDH1A1 1558/4885TSHR 487/4885LMNA 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.